Merus (MRUS) N.V. announced the launch of a proposed underwritten public offering of its common shares. All of the common shares are being offered by Merus. Merus currently intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to advance the clinical development of its product candidates, for preclinical research and technology development, and for working capital and general corporate purposes. Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital are acting as joint book-running managers for the offering. Van Lanschot Kempen is acting as lead manager for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus’s Strong Clinical Data and Financial Stability Justify Buy Rating
- Merus Announces Promising Phase 2 Trial Results
- Biohaven provides oncology program update
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz